JPRN-jRCTs042180148CompletedPhase 1
A pilot open-label clinical trial to evaluate decrease of brain amyloid beta(A-beta) by removing blood A-beta - A pilot open-label clinical trial to evaluate decrease of brain amyloid beta (A-beta) by removing blood A-beta
Yuzawa Yukio0 sites2 target enrollmentStarted: March 29, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 2
Study Overview
Brief Summary
There was no change in the amount of A beta accumulated in the brain by A beta imaging as the primary endpoint. By A beta removal apheresis.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- aroud 40 to around 85 (—)
- Sex
- All
Inclusion Criteria
- •non-diabetic MCI or mild AD of brain A-beta positive
Exclusion Criteria
- •1) diabetes
- •2) abnormal numbers of platelets or erythrocytes,
- •3) complication such as severe circulatory failure and heart failure,
- •4) medical histroy of cerebral vascular disease (infarct, hemorrhage)
Investigators
Similar Trials
Active, not recruiting
Not Applicable
An Open-Label, Dose-Escalation, Phase IB/ II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with Oral Everolimus in Subjects with Solid TumorsEstudio abierto de escalada de dosis de fase IB/II para investigar la seguridad, la farmacocinética, la farmacodinamia y la actividad clínica del inhibidor de MEK GSK1120212 en combinación con everolimus oral en pacientes con tumores sólidos.Cáncer de Pulmón no microcítico metastásicoMedDRA version: 13Level: LLTClassification code 10025055Term: Cáncer de pulmón de células no pequeñas, estadio IVEUCTR2009-017477-38-ESGlaxoSmithKline S.A.100
Active, not recruiting
Not Applicable
An Open-Label, Dose-Escalation, Phase IB/ II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with Oral Everolimus in Subjects with Solid TumorsEUCTR2009-017477-38-DEGlaxoSmithKline Research & Development Ltd100
Not yet recruiting
Not Applicable
A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumorsCancer (solid tumors)10027476NL-OMON53927Boehringer Ingelheim4
Recruiting
Phase 1
A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 or BI 907828 in combination with BI 754091 (ezabenlimab)advanced solid tumorJPRN-jRCT2080224759Boehringer Ingelheim170
Active, not recruiting
Phase 1
Study investigating intravenously administrated Oncocort in patients with metastatic prostate cancerEUCTR2016-003121-42-NLEnceladus Pharmaceuticals BV10